索拉非尼联合三氧化二砷对肝癌细胞株增殖及凋亡的影响
|
摘要
原发性肝癌(primary hepatic carcinoma,PHC)是常见的恶性肿瘤之一。我国是世界上肝癌的高发地区,肝癌死亡率居全国各种肿瘤的第2位,并且近10年来死亡率一直呈上升趋势。尽管近年来肝癌研究已取得了很大的进步,疗效也得到明显改观,但就肝癌整体疗效而言仍很不理想。目前,肝细胞癌的治疗方法主要包括手术治疗、肝动脉栓塞化疗(TACE)、冷冻治疗、射频消融、体外放疗、放射性粒子植入、生物治疗等。由于肝癌起病隐袭,多数患者就诊时肿瘤已进展至晚期,能行手术切除的肝癌尚不足25%。肝动脉栓塞化疗被证明有效,但并非所有病人都适合。全身化疗对晚期肝癌作用有限,单药化疗或联合化疗,其有效率均不足20%。故寻找一种合理有效的治疗晚期PHC方案具有重要意义。
索拉非尼(Sorafenib,nexavar)是一种双芳基尿素类口服多激酶抑制剂,其抗肿瘤机制包括两个方面。一方面可靶向作用于肿瘤细胞及肿瘤血管上的丝氨酸/苏氨酸激酶及受体酪氨酸激酶,通过抑制受体酪氨酸激酶KIT和FLT-3,以及Raf/MEK/ERK途径中丝氨酸/苏氨酸激酶,抑制肿瘤细胞增殖;另一方面,通过上游抑制受体酪氨酸激酶VEGFR和PDGFR,及下游抑制Raf/MEK/ERK途径中丝氨酸/苏氨酸激酶,抑制肿瘤血管生成。Scott M.Wilhelm等发现Sorafenib能通过抑制Raf-1及其相关的激酶、野生型或V599E突变型B-RAF的活性来阻断Raf/MEK/ERK信号传导通路,还能显著抑制一些酪氨酸激酶受体的活性,包括干细胞因子受体(KIT)、Fms样酪氨酸激酶(FLT-3)、血管内皮生长因子受体-2(VEGFR-2)、血管内皮生长因子受体-3(VEGFR-3)、血小板衍生生长因子受体-β(PDGFR-β)等。Li Liu等证实Sorafenib能下调肝癌细胞株PLC/PRF/5与HepG2的MEK、ERK蛋白磷酸化水平和cyclinD1水平,并且能下调eIE4E与抗凋亡蛋白Mcl-1水平,通过抑制MEK/ERK信号传导途径与MEK/ERK非依赖信号传导途径来抑制肝癌细胞增殖和诱导肝癌细胞凋亡。索拉非尼治疗肝癌的Ⅲ期双盲随机对照临床(SHARP)研究显示:与安慰剂相比,索拉非尼显著延长晚期HCC患者的总体生存达44%。索拉非尼组与安慰剂组中位OS分别为10.7个月及7.9个月,两组间差别有统计学意义。与安慰剂组相比,索拉非尼组的中位TTP更长(5.5个月对2.8个月),疾病控制率(DCR)更高(43%对32%)。已有临床试验表明,Sorafenib与化疗药如氮烯咪胺、紫杉醇、卡铂以及其他靶向药物如吉非替尼、贝伐单抗联用,能提高化疗药及其他靶向药物的抗肿瘤疗效。索拉非尼被确立成为第一个批准治疗晚期HCC的靶向治疗药物。三氧化二砷(Arsenic trioxide,As_2O_3)为中药砒霜、复方青黛的主要成分,我国学者将其用于白血病的治疗,取得了显著的成就。已有多项体内、体外研究发现As_2O_3对肝癌细胞有抑制增殖和诱导凋亡作用。
Sorafenib和As_2O_3在治疗肝细胞癌中抑制增殖、促进凋亡的机制不同,两药联合可多靶点,多途径治疗肝细胞癌。本研究主要从体外实验研究Sorafenib和As_2O_3联合对肝细胞癌的抑制作用,分析两药联合的性质,为进一步的临床应用提供实验依据。
本研究共分两个部分:
第一部分索拉非尼联合三氧化二砷对肝癌细胞株增殖抑制作用的研究
观察Sorafenib、As_2O_3单药和联用对HepG_2肝癌细胞株的增殖的抑制,比较两药联合作用与单药作用的差异以及分析两药的交互效应。
一、研究方法及内容
1.细胞培养:HepG2细胞在37℃、5%的CO_2孵箱中培养,培养基为含10%胎牛血清、1%的双抗(青霉素和链霉素)的RPMI 1640。细胞为上皮样细胞,每2～3d传代1次,并取对数生长期的细胞用于实验。
2.取对数生长期HepG2细胞种板,培养24 h后加入药物。实验分组:Somfenib6、3、1.5μmol/L和As_2O_3 4、2μmol/L分别组成单药组和Sorafenib+As_2O_3联合用药组,另设不加药的对照组,加药后分别培养24、48、72 h后,终止培养,加入MTT液,用酶标仪(波长570 nml)测定各孔的OD值。根据下列公式计算对HepG2细胞的抑制率:抑制率=(1-实验药物组OD值/空白对照组OD值)×100%
3.统计方法:所有数据采用SPSS 13.0统计软件进行统计处理,实验数据用均数±标准差((?)±s)表示。两样本均数的比较采用Independent-Samples T Test,多组间均数比较采用One-way ANOVA,post hoc test方差齐性采用LSD法,方差不齐的采用Dunnett T3法。交互效应分析采用factorial analysis。P＜0.05有统计学意义。
二、主要结果
1.MTT法检测显示,不同浓度的Sorafenib、As_2O_3单药对HepG2细胞均有抑制增殖的作用(P＜0.05)。Sorafenib与As_2O_3联合作用于HepG2细胞分别较两单药抑制作用更强(P＜0.05)。
2.Sorafenib和As_2O_3联用在24h、48h、72h均有协同作用(P＜0.05)。
三、主要结论
两药单用及联用对HepG2细胞均有抑制增殖的作用,两药联用较之单药的抑制作用更强,两药联用的性质为协同。
第二部分索拉非尼联合三氧化二砷对肝癌细胞株的凋亡诱导作用及机制研究
观察Sorafenib、As_2O_3单药和联用对HepG_2肝癌细胞的凋亡的诱导作用,探讨两药单用与联用诱导凋亡的可能机制。
一、研究方法及内容
1.实验分组:Sorafenib 4μmol/L,As_2O_3 3μmol/L,联合组Sorafenib 4μmol/L+As_2O_3 3μmol/L,另设不加药的对照组。细胞培养:HepG2细胞在37℃、5%的CO_2孵箱中培养,培养基为含10%胎牛血清、1%的双抗(青霉素和链霉素)的RPMI 1640。细胞为上皮样细胞,每2～3 d传代1次,并取对数生长期的细胞用于实验。
2.Annexin V-FITC/PI双染检测细胞凋亡。取对数生长期的人肝癌细胞株HepG2,用0.25%胰蛋白酶消化,加入含10%胎牛血清的RPMI-1640培养液制备成浓度为2×10~5/ml的细胞悬液,接种2.5ml/孔于6孔培养板中,使其细胞数为5×10~5个/孔。培养24h后取出培养板,对照组加入RPMI-1640培养液0.5ml;索拉非尼组添加稀释的Sorafenib药液0.5ml至终浓度3μmol/L;三氧化二砷组加入稀释的As_2O_3药液0.5ml至终浓度4μmol/L;联合用药组加入稀释的As_2O_3药液0.25ml至终浓度4μmol/L,稀释的索拉非尼药液0.25ml至终浓度为3μmol/L。置于37℃、5%CO_2培养箱继续培养48h。取出培养板,胰蛋白酶消化,收集细胞离心2000rpm×5min,弃去上清液。PBS洗涤。加入500μL的Binding Buffer悬浮细胞,加入5μL AnnexinV-FITC混匀后,加入5μL Propidium Iodide,混匀。室温避光反应5～15min。1小时内进行流式细胞仪检测。
3.罗丹明123染色检测细胞线粒体膜电位变化。细胞培养及药物处理同前述。加药后48h收集细胞。加入罗丹明123染液10μg/mL。37℃,5%CO_2细胞培养箱孵育10 min,离心以培养基洗细胞两次。重悬细胞于培养基中,37℃,5%CO_2培养60 min。流式细胞仪检测。计算相对荧光强度,相对荧光强度=加药组荧光强度/对照组荧光强度。
4.比色法检测caspase-3的活化程度。细胞培养及药物处理基本同前述。加药后48h收集细胞。用PBS洗涤细胞2次。在收集的沉淀细胞中加/250μL冰冷LysisBuffer,吹打均匀。置冰上裂解30min,其间涡旋振荡3～4次,每次10 s。4℃,离心(10,000 rpm)1 min。小心吸取上清转移至新的管中,并放置冰上待用。取1μL上清,常规方法BCA法测定其中的蛋白浓度。吸取50μL含200μg蛋白的细胞裂解上清。加入50μL的2×Reaction Buffer,使用前每50μL 2×Reaction Buffer加入0.5μL DTT。加入5μL Caspase-3 Substrate并于37℃避光孵育4h。用酶标仪在λ=405nm测定其吸光值。通过计算OD_(处理组)/OD_(对照组)的倍数来确定处理组Caspase-3活化程度。
5.统计方法:所有数据采用SPSS 13.0统计软件进行统计处理,实验数据用均数±标准差((?)±s)表示,均数比较采用one-way ANOVA。post hoc test方差齐性采用LSD法,方差不齐的采用Dunnett T3法。P＜0.05有统计学意义。
二、主要结果
1.As_2O_3 4μmol/L与Sorafenib 3μmol/L及联合组作用于HepG2细胞24h后检测细胞的早期凋亡率,As_2O_3 4μmol/L单药、Somfenib 3μmol/L单药、As_2O_3 4μmol/L+Sorafenib 3μmol/L联合组及对照组的差异有统计学意义(P＜0.05)。进一步两两比较显示,联合组较Sorafenib单药、As_2O_3单药、对照组的早期凋亡率的差异均有统计学意义(P＜0.05)。较之As_2O_3、Sorafenib单药组,联合组对HepG2细胞凋亡诱导作用更强。
2.检测线粒体膜电位罗丹明123染色后的荧光强度,计算相对荧光强度。As_2O_34μmol/L单药、Sorafenib 3μmol/L单药、As_2O_3 4μmol/L+Sorafenib 3μmol/L联合组及对照组的差异有统计学意义(P＜0.05)。进一步两两比较显示,联合组较Sorafenib单药、As_2O_3单药、对照组的相对荧光强度变化均有统计学意义(P＜0.05)。即较之As_2O_3、Sorafenib单药组,药物联合作用后HepG2细胞线粒体膜电位下降更大。
3.比色法检测caspase-3的活化程度。As_2O_3 4μmol/L单药、Sorafenib 3μmol/L单药、As_2O_3 4μmol/L+Sorafenib 3μmol/L联合组及对照组的OD_(处理组)/OD_(对照组)的差异有统计学意义(P＜0.05)。进一步两两比较显示,联合组较Sorafenib单药、As_2O_3单药的Caspase-3活化程度均有统计学意义(P＜0.05)。较之As_2O_3、Sorafenib单药组,药物联合作用于HepG2细胞后Caspase-3活化程度更大,诱导细胞凋亡的作用更强。
三、主要结论
与Sorafenib、As_2O_3单独用药比较,联合用药诱导凋亡的作用更强。联合用药凋亡诱导作用增强可能与两药作用于信号传导通路的不同靶位,导致caspase-3蛋白活化增加、线粒体凋亡途径激活增强有关。
Primary hepatic carcinoma(PHC) is considered as one of the most common cancer in the world.And it has been ranked as the second cause of cancer mortality in China.The potentially curative therapies of late stage hepatocellular carcinoma (HCC) are low effective,so finding active and reasonable treatments is significant.
Sorafenib is a multikinase inhibitor that has shown to block tumor cell proliferation and angiogenesis by inhibiting serine/threonine kinases,as well as the receptor tyrosine kinases vascular endothelial growth factor receptor 2(VEGFR2), vascular endothelial growth factor receptor 3(VEGFR3),platelet-derived growth factor receptor(PDGFR),FLT3 and C-KIT.In 2007 ASCO manual meeting,a phaseⅢrandomized placebo-controlled trial(SHARP trial) was reported.It confirmed that Sorafenib improved 44%of HCC patients' survival time than the placebo,MST was 10.7 months and TTP was 5.5 months in the Sorafenib team.At the end of 2007, FDA approved sorafenib for patients with inoperable liver cancer.Arsenic trioxide (As_2O_3) has shown remarkable curative effect in the treatment of acute promyelocytic Leukemia(APL).Studies have showed that As_2O_3 could inhibition of HCC in vitro and in vivo.
As Sorafenib and As_2O_3 has different mechanism of inducing apoptosis and inhibiting proliferation on tumor cell,it is possible that the two drugs can treat HCC through different ways and targets.This study was designed to investigate that the nature of sorafenib combined with As_2O_3 on hepatocellular carcinoma cells.
The first part:Inhibitory proliferation effect of Sorafenib combined with Arsenic trioxide on hepatocellular carcinoma cells
Methods:
1.HepG2 human HCC tumor cells were cultured with RPMI 1640 containing 10%fetal calf serum.Cells in exponentially growing period were chosen for experiment.HepG2 cells were divided into 4 groups:control group,Sorafenib-treated group,As_2O_3-treated group and combination treatment group.MTT assay analyzed cells treated with Sorafenib(1.5、3、6μmol/L) alone,As_2O_3(2、4μmol/L) alone,Sorafenib combined As_2O_3 and cells of control group for 24, 48 and 72 hours respectively.The inhibitory rates of cells were calculated according OD value.
2.Statistical analysis:All datas were analysised by SPSS 13.0 statistical software. Datas were expressed as(?)±s.The inhibitory rates were analyzed by One-way ANOVA followed by post hoc test.P＜0.05 was considered to be significant.
Results:
1.The MTT result indicated:Sorafenib,As_2O_3 alone or together could inhibit the proliferation of HepG2 cells(P＜0.05).Sorafenib combined with As_2O_3 enhanced inhibition of proliferation in HepG2 cells(P＜0.05).
2.There was a synergistic effect in Sorafenib combined with As_2O_3 at 24h,48h,72h on HepG2 cells(P＜0.05).
Conclusion:
Sorafenib,As_2O_3 alone or together could inhibit the proliferation of HepG2 cells, the combination of Sorafenib and As_2O_3 showed stronger inhibition.The nature of the interaction of combination was synergistic.
The second part:Induction apoptosis effect of Sorafenib combined with Arsenic trioxide on hepatocellular carcinoma cells
Methods:
1.HepG2 human HCC tumor cells were cultured as the above mentioned.Cells of exponentially growing period were chosen for experiment.HepG2 cells were divided into 4 groups:control group,Sorafenib-treated group(Sorafenib 3μmol/L), As_2O_3-treated group(As_2O_3 4μmol/L) and combination treatment group(Sorafenib 3μmol/L+As_2O_3 4μmol/L).
2.Group as the above mentioned,the apoptosis rate of HepG2 cells labeled by Annexin V-FITC/PI was observed by FCM.
3.Group as the above mentioned,cells collected and that changes of mitochondrial membrane potential(Δψm) labeled by Rhodamine123 was examined by FCM.
4.Group as the above mentioned,the activity of caspase-3 were examined by colorimetric.
5.Statistical analysis:All datas were analysised by SPSS 13.0 statistical software. Datas were expressed as(?)±s.The data were analyzed by One-way ANOVA followed by post hoc test.P＜0.05 was considered to be significant.
Results:
1.Compared with untreated control,Sorafenib,As_2O_3 alone and together induced more HepG2 cells apoptosis(P＜0.05).Induction of cell apoptosis was enhanced by combinaton of Sorafenib and As_2O_3 compared with each agent alone.
2.The mitochondrial membrane potential(Δψm) was decreased by As_2O_3,sorafenib alone or combination.The effect of the agents combined was stronger than that alone (P＜0.05).
3.The activity of the caspase-3 increased in the three treated groups.At the same time,the combination group increased more significantly than the Sorafenib group, As_2O_3 group alone respectively.
Conclusion:
Sorafenib combined with As_2O_3 showed synergistic effect on induction apoptosis of HepG2 cells.The mechanisms were closely related to the promotion of apoptosis by influence several signaling pathways such as the mitochondria-dependent and caspase- dependent ways.
索拉非尼(Sorafenib,nexavar)是一种双芳基尿素类口服多激酶抑制剂,其抗肿瘤机制包括两个方面。一方面可靶向作用于肿瘤细胞及肿瘤血管上的丝氨酸/苏氨酸激酶及受体酪氨酸激酶,通过抑制受体酪氨酸激酶KIT和FLT-3,以及Raf/MEK/ERK途径中丝氨酸/苏氨酸激酶,抑制肿瘤细胞增殖;另一方面,通过上游抑制受体酪氨酸激酶VEGFR和PDGFR,及下游抑制Raf/MEK/ERK途径中丝氨酸/苏氨酸激酶,抑制肿瘤血管生成。Scott M.Wilhelm等发现Sorafenib能通过抑制Raf-1及其相关的激酶、野生型或V599E突变型B-RAF的活性来阻断Raf/MEK/ERK信号传导通路,还能显著抑制一些酪氨酸激酶受体的活性,包括干细胞因子受体(KIT)、Fms样酪氨酸激酶(FLT-3)、血管内皮生长因子受体-2(VEGFR-2)、血管内皮生长因子受体-3(VEGFR-3)、血小板衍生生长因子受体-β(PDGFR-β)等。Li Liu等证实Sorafenib能下调肝癌细胞株PLC/PRF/5与HepG2的MEK、ERK蛋白磷酸化水平和cyclinD1水平,并且能下调eIE4E与抗凋亡蛋白Mcl-1水平,通过抑制MEK/ERK信号传导途径与MEK/ERK非依赖信号传导途径来抑制肝癌细胞增殖和诱导肝癌细胞凋亡。索拉非尼治疗肝癌的Ⅲ期双盲随机对照临床(SHARP)研究显示:与安慰剂相比,索拉非尼显著延长晚期HCC患者的总体生存达44%。索拉非尼组与安慰剂组中位OS分别为10.7个月及7.9个月,两组间差别有统计学意义。与安慰剂组相比,索拉非尼组的中位TTP更长(5.5个月对2.8个月),疾病控制率(DCR)更高(43%对32%)。已有临床试验表明,Sorafenib与化疗药如氮烯咪胺、紫杉醇、卡铂以及其他靶向药物如吉非替尼、贝伐单抗联用,能提高化疗药及其他靶向药物的抗肿瘤疗效。索拉非尼被确立成为第一个批准治疗晚期HCC的靶向治疗药物。三氧化二砷(Arsenic trioxide,As_2O_3)为中药砒霜、复方青黛的主要成分,我国学者将其用于白血病的治疗,取得了显著的成就。已有多项体内、体外研究发现As_2O_3对肝癌细胞有抑制增殖和诱导凋亡作用。
Sorafenib和As_2O_3在治疗肝细胞癌中抑制增殖、促进凋亡的机制不同,两药联合可多靶点,多途径治疗肝细胞癌。本研究主要从体外实验研究Sorafenib和As_2O_3联合对肝细胞癌的抑制作用,分析两药联合的性质,为进一步的临床应用提供实验依据。
本研究共分两个部分:
第一部分索拉非尼联合三氧化二砷对肝癌细胞株增殖抑制作用的研究
观察Sorafenib、As_2O_3单药和联用对HepG_2肝癌细胞株的增殖的抑制,比较两药联合作用与单药作用的差异以及分析两药的交互效应。
一、研究方法及内容
1.细胞培养:HepG2细胞在37℃、5%的CO_2孵箱中培养,培养基为含10%胎牛血清、1%的双抗(青霉素和链霉素)的RPMI 1640。细胞为上皮样细胞,每2～3d传代1次,并取对数生长期的细胞用于实验。
2.取对数生长期HepG2细胞种板,培养24 h后加入药物。实验分组:Somfenib6、3、1.5μmol/L和As_2O_3 4、2μmol/L分别组成单药组和Sorafenib+As_2O_3联合用药组,另设不加药的对照组,加药后分别培养24、48、72 h后,终止培养,加入MTT液,用酶标仪(波长570 nml)测定各孔的OD值。根据下列公式计算对HepG2细胞的抑制率:抑制率=(1-实验药物组OD值/空白对照组OD值)×100%
3.统计方法:所有数据采用SPSS 13.0统计软件进行统计处理,实验数据用均数±标准差((?)±s)表示。两样本均数的比较采用Independent-Samples T Test,多组间均数比较采用One-way ANOVA,post hoc test方差齐性采用LSD法,方差不齐的采用Dunnett T3法。交互效应分析采用factorial analysis。P＜0.05有统计学意义。
二、主要结果
1.MTT法检测显示,不同浓度的Sorafenib、As_2O_3单药对HepG2细胞均有抑制增殖的作用(P＜0.05)。Sorafenib与As_2O_3联合作用于HepG2细胞分别较两单药抑制作用更强(P＜0.05)。
2.Sorafenib和As_2O_3联用在24h、48h、72h均有协同作用(P＜0.05)。
三、主要结论
两药单用及联用对HepG2细胞均有抑制增殖的作用,两药联用较之单药的抑制作用更强,两药联用的性质为协同。
第二部分索拉非尼联合三氧化二砷对肝癌细胞株的凋亡诱导作用及机制研究
观察Sorafenib、As_2O_3单药和联用对HepG_2肝癌细胞的凋亡的诱导作用,探讨两药单用与联用诱导凋亡的可能机制。
一、研究方法及内容
1.实验分组:Sorafenib 4μmol/L,As_2O_3 3μmol/L,联合组Sorafenib 4μmol/L+As_2O_3 3μmol/L,另设不加药的对照组。细胞培养:HepG2细胞在37℃、5%的CO_2孵箱中培养,培养基为含10%胎牛血清、1%的双抗(青霉素和链霉素)的RPMI 1640。细胞为上皮样细胞,每2～3 d传代1次,并取对数生长期的细胞用于实验。
2.Annexin V-FITC/PI双染检测细胞凋亡。取对数生长期的人肝癌细胞株HepG2,用0.25%胰蛋白酶消化,加入含10%胎牛血清的RPMI-1640培养液制备成浓度为2×10~5/ml的细胞悬液,接种2.5ml/孔于6孔培养板中,使其细胞数为5×10~5个/孔。培养24h后取出培养板,对照组加入RPMI-1640培养液0.5ml;索拉非尼组添加稀释的Sorafenib药液0.5ml至终浓度3μmol/L;三氧化二砷组加入稀释的As_2O_3药液0.5ml至终浓度4μmol/L;联合用药组加入稀释的As_2O_3药液0.25ml至终浓度4μmol/L,稀释的索拉非尼药液0.25ml至终浓度为3μmol/L。置于37℃、5%CO_2培养箱继续培养48h。取出培养板,胰蛋白酶消化,收集细胞离心2000rpm×5min,弃去上清液。PBS洗涤。加入500μL的Binding Buffer悬浮细胞,加入5μL AnnexinV-FITC混匀后,加入5μL Propidium Iodide,混匀。室温避光反应5～15min。1小时内进行流式细胞仪检测。
3.罗丹明123染色检测细胞线粒体膜电位变化。细胞培养及药物处理同前述。加药后48h收集细胞。加入罗丹明123染液10μg/mL。37℃,5%CO_2细胞培养箱孵育10 min,离心以培养基洗细胞两次。重悬细胞于培养基中,37℃,5%CO_2培养60 min。流式细胞仪检测。计算相对荧光强度,相对荧光强度=加药组荧光强度/对照组荧光强度。
4.比色法检测caspase-3的活化程度。细胞培养及药物处理基本同前述。加药后48h收集细胞。用PBS洗涤细胞2次。在收集的沉淀细胞中加/250μL冰冷LysisBuffer,吹打均匀。置冰上裂解30min,其间涡旋振荡3～4次,每次10 s。4℃,离心(10,000 rpm)1 min。小心吸取上清转移至新的管中,并放置冰上待用。取1μL上清,常规方法BCA法测定其中的蛋白浓度。吸取50μL含200μg蛋白的细胞裂解上清。加入50μL的2×Reaction Buffer,使用前每50μL 2×Reaction Buffer加入0.5μL DTT。加入5μL Caspase-3 Substrate并于37℃避光孵育4h。用酶标仪在λ=405nm测定其吸光值。通过计算OD_(处理组)/OD_(对照组)的倍数来确定处理组Caspase-3活化程度。
5.统计方法:所有数据采用SPSS 13.0统计软件进行统计处理,实验数据用均数±标准差((?)±s)表示,均数比较采用one-way ANOVA。post hoc test方差齐性采用LSD法,方差不齐的采用Dunnett T3法。P＜0.05有统计学意义。
二、主要结果
1.As_2O_3 4μmol/L与Sorafenib 3μmol/L及联合组作用于HepG2细胞24h后检测细胞的早期凋亡率,As_2O_3 4μmol/L单药、Somfenib 3μmol/L单药、As_2O_3 4μmol/L+Sorafenib 3μmol/L联合组及对照组的差异有统计学意义(P＜0.05)。进一步两两比较显示,联合组较Sorafenib单药、As_2O_3单药、对照组的早期凋亡率的差异均有统计学意义(P＜0.05)。较之As_2O_3、Sorafenib单药组,联合组对HepG2细胞凋亡诱导作用更强。
2.检测线粒体膜电位罗丹明123染色后的荧光强度,计算相对荧光强度。As_2O_34μmol/L单药、Sorafenib 3μmol/L单药、As_2O_3 4μmol/L+Sorafenib 3μmol/L联合组及对照组的差异有统计学意义(P＜0.05)。进一步两两比较显示,联合组较Sorafenib单药、As_2O_3单药、对照组的相对荧光强度变化均有统计学意义(P＜0.05)。即较之As_2O_3、Sorafenib单药组,药物联合作用后HepG2细胞线粒体膜电位下降更大。
3.比色法检测caspase-3的活化程度。As_2O_3 4μmol/L单药、Sorafenib 3μmol/L单药、As_2O_3 4μmol/L+Sorafenib 3μmol/L联合组及对照组的OD_(处理组)/OD_(对照组)的差异有统计学意义(P＜0.05)。进一步两两比较显示,联合组较Sorafenib单药、As_2O_3单药的Caspase-3活化程度均有统计学意义(P＜0.05)。较之As_2O_3、Sorafenib单药组,药物联合作用于HepG2细胞后Caspase-3活化程度更大,诱导细胞凋亡的作用更强。
三、主要结论
与Sorafenib、As_2O_3单独用药比较,联合用药诱导凋亡的作用更强。联合用药凋亡诱导作用增强可能与两药作用于信号传导通路的不同靶位,导致caspase-3蛋白活化增加、线粒体凋亡途径激活增强有关。
Primary hepatic carcinoma(PHC) is considered as one of the most common cancer in the world.And it has been ranked as the second cause of cancer mortality in China.The potentially curative therapies of late stage hepatocellular carcinoma (HCC) are low effective,so finding active and reasonable treatments is significant.
Sorafenib is a multikinase inhibitor that has shown to block tumor cell proliferation and angiogenesis by inhibiting serine/threonine kinases,as well as the receptor tyrosine kinases vascular endothelial growth factor receptor 2(VEGFR2), vascular endothelial growth factor receptor 3(VEGFR3),platelet-derived growth factor receptor(PDGFR),FLT3 and C-KIT.In 2007 ASCO manual meeting,a phaseⅢrandomized placebo-controlled trial(SHARP trial) was reported.It confirmed that Sorafenib improved 44%of HCC patients' survival time than the placebo,MST was 10.7 months and TTP was 5.5 months in the Sorafenib team.At the end of 2007, FDA approved sorafenib for patients with inoperable liver cancer.Arsenic trioxide (As_2O_3) has shown remarkable curative effect in the treatment of acute promyelocytic Leukemia(APL).Studies have showed that As_2O_3 could inhibition of HCC in vitro and in vivo.
As Sorafenib and As_2O_3 has different mechanism of inducing apoptosis and inhibiting proliferation on tumor cell,it is possible that the two drugs can treat HCC through different ways and targets.This study was designed to investigate that the nature of sorafenib combined with As_2O_3 on hepatocellular carcinoma cells.
The first part:Inhibitory proliferation effect of Sorafenib combined with Arsenic trioxide on hepatocellular carcinoma cells
Methods:
1.HepG2 human HCC tumor cells were cultured with RPMI 1640 containing 10%fetal calf serum.Cells in exponentially growing period were chosen for experiment.HepG2 cells were divided into 4 groups:control group,Sorafenib-treated group,As_2O_3-treated group and combination treatment group.MTT assay analyzed cells treated with Sorafenib(1.5、3、6μmol/L) alone,As_2O_3(2、4μmol/L) alone,Sorafenib combined As_2O_3 and cells of control group for 24, 48 and 72 hours respectively.The inhibitory rates of cells were calculated according OD value.
2.Statistical analysis:All datas were analysised by SPSS 13.0 statistical software. Datas were expressed as(?)±s.The inhibitory rates were analyzed by One-way ANOVA followed by post hoc test.P＜0.05 was considered to be significant.
Results:
1.The MTT result indicated:Sorafenib,As_2O_3 alone or together could inhibit the proliferation of HepG2 cells(P＜0.05).Sorafenib combined with As_2O_3 enhanced inhibition of proliferation in HepG2 cells(P＜0.05).
2.There was a synergistic effect in Sorafenib combined with As_2O_3 at 24h,48h,72h on HepG2 cells(P＜0.05).
Conclusion:
Sorafenib,As_2O_3 alone or together could inhibit the proliferation of HepG2 cells, the combination of Sorafenib and As_2O_3 showed stronger inhibition.The nature of the interaction of combination was synergistic.
The second part:Induction apoptosis effect of Sorafenib combined with Arsenic trioxide on hepatocellular carcinoma cells
Methods:
1.HepG2 human HCC tumor cells were cultured as the above mentioned.Cells of exponentially growing period were chosen for experiment.HepG2 cells were divided into 4 groups:control group,Sorafenib-treated group(Sorafenib 3μmol/L), As_2O_3-treated group(As_2O_3 4μmol/L) and combination treatment group(Sorafenib 3μmol/L+As_2O_3 4μmol/L).
2.Group as the above mentioned,the apoptosis rate of HepG2 cells labeled by Annexin V-FITC/PI was observed by FCM.
3.Group as the above mentioned,cells collected and that changes of mitochondrial membrane potential(Δψm) labeled by Rhodamine123 was examined by FCM.
4.Group as the above mentioned,the activity of caspase-3 were examined by colorimetric.
5.Statistical analysis:All datas were analysised by SPSS 13.0 statistical software. Datas were expressed as(?)±s.The data were analyzed by One-way ANOVA followed by post hoc test.P＜0.05 was considered to be significant.
Results:
1.Compared with untreated control,Sorafenib,As_2O_3 alone and together induced more HepG2 cells apoptosis(P＜0.05).Induction of cell apoptosis was enhanced by combinaton of Sorafenib and As_2O_3 compared with each agent alone.
2.The mitochondrial membrane potential(Δψm) was decreased by As_2O_3,sorafenib alone or combination.The effect of the agents combined was stronger than that alone (P＜0.05).
3.The activity of the caspase-3 increased in the three treated groups.At the same time,the combination group increased more significantly than the Sorafenib group, As_2O_3 group alone respectively.
Conclusion:
Sorafenib combined with As_2O_3 showed synergistic effect on induction apoptosis of HepG2 cells.The mechanisms were closely related to the promotion of apoptosis by influence several signaling pathways such as the mitochondria-dependent and caspase- dependent ways.
引文
[1]陈建国,宋新明.中国肝癌发病水平的估算及分析[J].中国肿瘤,2005,14(1):28-31.
[2]黄正京,周麦耕,王黎君.中国肝癌死亡率和乙肝病毒表面抗原携带率的地理分布研究[J].疾病监测,2007,22(4):242-245.
[3]Llovet JM,Bruix J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:Chemoembolization improves survival[J].Hepatology,2003,37(2):429-442
[4]Scott M,Wilhelm,Christopher Carter,Li Ya Tang,et al.BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J].Cancer Research,2004,64:7099-7109.
[5]Li Liu,Yichen Cao,Charles Chen,et al.Sorafenib blocks the RAF/MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J].Cancer Research,2006,66(24):11851-11858.
[6]Wilhelm S,Chien DS.BAY 43-9006:Preclinical data[J].Curr Pharm Des,2002,8(25):2255-2257.
[7]Llovet J,Ricci S,Mazzaferro V,et al.Sorafenib improves survival in advanced Hepatocellular Carcinoma(HCC):Results of a Phase Ⅲ randomized placebo-controlled trial(SHARP trial)[J].J Clin Oncol,2007 ASCO Annual Meeting Proceedings Part Ⅰ.Vol 25,No.18s(June 20 Supplement),2007:LBA1.
[8]McDermott DF,Sosman JA,Gonzalez R,et al.Double-blind randomized phase Ⅱ study of the combination of sorafenib and dacarbazine in patients with advanced melanoma:a report from the 11715 Study Group[J].J Clin Oncol,2008,26(13):2178-85.
[9]Flaherty KT,Lee RJ,Humphries R,et al.Phase Ⅰ trial of BAY 43-9006 in combination with carboplatin(C) and paclitaxel(P)[J].Proc Am Soc Clin Oncol,2003,22:710.
[10]Flaherty KT,Brose M,Schuchter LM,et al.Sorafenib combined with carboplatin and paclitaxel for metastatic melanoma:PFS and response versus B-Raf status.Ann Oncol,2006,17:ⅲ33.
[11]Adjei AA,Molina JR,Mandrekar SJ,et al.Phase Ⅰ study of Sorefenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer[J].Clin Cancer Res,2007,13(9):2684-2691.
[12]Azad NS,Posadas EM,Kwitkowski VE,et al.Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab.J Clin Oncol,2006 ASCO Annual Meeting Proceedings Part Ⅰ.Vol 24,No.18s(June 20 Supplement),2006:3004.
[13]Posadas EM,Kwitkowski V,Liel MS et al.Clinical synergism from combinational VEGF signal transduction inhibition in patients with advanced solid tumors-early results from a Phase Ⅰ study of sorafenib(BAY 43-9006)and bevacizumab[J].Eur J Cancer Suppl,2005,3:419.
[14]徐洪雨,高媛媛,武倩丽等.三氧化二砷抑制人肝癌细胞株增殖和诱导凋亡作用[J].世界华人消化杂志,2000,8(11):1233-1237.
[15]邓志华,蔡洪培,李石等.三氧化二砷对正常肝细胞及肝癌细胞株的影响[J].中华消化杂志,1999,19(4):227-279.
[16]陈洪,秦叔逵,陈惠英等.三氧化二砷对抗肝癌作用的实验研究[J].中华肝病杂志,2000,8(1):27-29.
[17]邬红霞,周艳,于志坚等.三氧化二砷联合羟基喜树碱抗肝癌作用的实验研究[J].临床肿瘤学杂志,2007,6(12):413-416.
[18]Wei Wang,Shu-Kui Qin,Bao-An Chen et al.Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma[J].World J Gastroenterol,2001,7(5):702-705.
[19]Bos JL.Ras oncogenes in human cancer:a review[J].Cancer Res,1989,49(17):4682-4689.
[20]张鹏,胡龙虎,周晋,等.三氧化二砷治疗急性早幼粒细胞白血病的机 制研究[J].白血病,1996,5(3):131-133.
[21]陈国强,陈赛娟,王振义,等.氧化砷注射液治疗早幼粒细胞白血病的机制及展望[J].中国中西医结合杂志,1998,18(10):581-582.
[22]杜彩文,李德锐,杜英城,等.三氧化二砷诱导人鼻咽低分化鳞癌裸鼠移植瘤细胞分化的研究[J].癌症,2003,22(1):21-25.
[23]Baj G,Arnulfo A,Deaglio S,et al.Arsenic trioxide and breast cancer:analysis of the apoptotic,differentiation and immuno-modulatory effects[J].J Breast Cancer Res Treat,2002,73(1):61-73.
[24]Zhu Q,Zhang JW,Zhu Ha,et al.Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk[J].J Blood,2002,99(3):1014-1022.
[25]邓友平,林晨,张雪艳,等.三氧化二砷诱导人胃腺癌SGC-7901细胞程序化死亡并降低c-myc基因的表达[J].药学学报,1999,34(5):1-4.
[26]邓志华,蔡洪培,李石,等.三氧化二砷对正常肝细胞及肝癌细胞株的影响.[J].中华消化杂志,1999,19(4):227-279.
[27]刘琳,秦叔逵,陈惠英,等.三氧化二砷对人肝癌细胞株选择性抑制作用的实验研究[J].临床肿瘤学杂志,1999,4(4):39-41.
[28]刘琳,秦叔逵,陈惠英,等.三氧化二砷选择性诱导人肝癌细胞凋亡及相关基因的实验研究[J].中华肝脏病杂志,2000,8(6):70-73.
[29]邓友平,林晨,张雪艳,等.三氧化二砷抗肿瘤作用的研究[J].中国中药杂志,1999,24(3):174-175.
[30]蔡洪培,谢渭芬,陈岳祥,等.三氧化二砷对腹腔荷瘤裸鼠的抗恶病质效应[J].第二军医大学学报,2002,23(3):279-280.
[31]闻勤生,罗俊卿,焦成松.三氧化二砷对肝癌HepG2细胞增殖的影响[J].第四军医大学学报,2001,22(9):828-830.
[32]闻勤生,罗俊卿,焦成松.三氧化二砷诱导肝癌细胞HepG2凋亡作用[J].第三军医大学学报,2001,23(8):913-914.
[33]沈忠英,沈健,陈铭华.氧化砷诱导食管癌细胞系细胞凋亡的研究[J].汕头大学医学院学报,2001,14(1):1-4.
[34]张勇,李志民,刘音.三氧化二砷局部注射治疗原发性肝癌的临床研究[J].中华医学写字杂志,2002,9(16):1246-1248.
[35]陈俊强,李绍森,彭民浩,等.三氧化二砷及6种抗癌药物对肝癌细胞株作用的对比研究[J].中国普外基础与临床杂志,2001,8(6):367-369.
[36]罗俊卿,闻勤生,焦成松.三氧化二砷对肝癌细胞增殖的影响[J].临床消化病杂志,2001,13(3):113-115.
[37]Wang W,Qin S K,Chen B A,et al.Experimental study on anti-tumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma[J].J World J Gastroenterol,2001,7(5):702-705.
[38]Richly H,Henning BF,Kupsch P,et al.Results of a Phase Ⅰ trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors[J].J Ann Oncol,2006,17(5):866-873.
[39]Abou-Alfa G,Johnson P,Knox J,et al.Preliminary results from a Phase Ⅱ,randomized,double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma[J].J European Journal of Cancer,2007,5(Suppl):3500.
[40]Kanzler S,Galle PR.Apoptosis and the liver[J].Semin Cancer Biol,2000,10:173-184.
[41]曾益新.肿瘤学[M].北京:人民卫生出版社,2003.209-236.
[42]Wyllie AH.Apoptosis and carcinognenesis.Eur J Cell Biol,1997,73(3):189-197.
[43]Askenazi A,D ixit VM.Death receptors:signaling and modulation[J].Science,1998,281(5381):1305-1308.
[44]Green D R,Reed J C.Mitochondrial and apoptosis[J].Science,1998,281(5381):1309-1312.
[45]Stewart J H,Nguyen D,Chen G A,et al.Induction of apoptosis in malignant pleuralmesothlioma cells by activaction of the Fas(APO-1/CD95) death signal pathway[J].J Thorac Cardiovase Surg,2002,123(2):295-302.
[46]Kroemer G,Reed J C.Mitochondrial control of cell death[J].Nat Med,2000,6(5):513-519.
[47]Susin SA,Lorenzo HK,Zamami N,et al.Moleuclar characterization of mitochondrial apoptosis inducing factor[J].Nature,1999,397(6718):441-446.
[48]Zoratti M and Szaboi Z.The mitochondrial permeability transition.Biochem Biophys Acta,1995,1241(2):139-176.
[49]Stewart J H,Nguyen D,Chen G A,et al.Induction of apoptosis in malignant pleural mesothlioma cells by activaction of the Fas(APO-1/CD95) death signal pathway[J].J Thorac Cardiovase Surg,2002,123(2):295-302.
[50]Herr I,Debatin K.Cellular stress response and apoptosis in cancer therapy[J].Blood,2001,98(9):2603-2604.
[51]Hascgawa J,Kamada S,Kamijke W,et al.Involvement ofCPP32/Yama(-like)protease in Fas-mediated apoptosis[J].Cancer Res,1996,56(8):1713-1718.
[52]Perkins C,Kim CN,Fang G,et al.Arsenic induces apoptosis of multi-drugresistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR,MRP,Bcl-2 or bcl-x(L)[J].Blood,2000,95(3):1014-1022.
[53]Pu YS,Hour TC,Chen J,et al.Arsenic trioxide as a novel anticancer agent against human transitional carcinoma characterizing its apoptotic pathway[J].Anticancer Drugs,2002,13(3):293-300.
[54]Soignet SL,Maslak P,Wang ZG,et al.Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide[J].New Engl J Med,1998,339(19):1341-1348.
[55]Akao Y,Mizoguchi H,Kojima S,et al.Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro:activation of caspases and down-regulation of Bcl-2 protein[J].Br J Haematol,1998,102(4):1055-1060.
[56]Shin S,SungBJ,Cho YS,et al.An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7[J|.Bio Chem,2001,40(4):1117-1123.
[57]鞠培新,石文君.三氧化二砷在诱导非小细胞肺癌NCI-H157细胞凋亡过程中对Survivin基因表达Caspase-3的影响[J].中国肿瘤临床,2007, 34(19):1097-1100.
[58]Jin S,Zhuo Y,Guo W,et al.P21-activated Kinase 1(Pakl)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization,phosphorylation of BAD,and Bcl-2 association[J].J Biol Chem,2005,280(26):24698-24705.
[59]Salomoni P,Wasik MA,Riedel RF,et al.Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant[J].J Exp Med 1998,187(12):1995-2007.
[60]Chen J,Fujii K,Zhang L,et al.Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism.Proc Natl Acad Sci USA,2001,98(14):7783-7788.
[61]Baumann B,Weber CK,Troppmair J,et al.Raf induces NF-kappaB by membrane shuttle kinase MEKK1,a signaling pathway critical for transformation.Proc N ATL ACAD Sci USA,2000,97(9):4615-4620.
[62]Le Mellay V,Troppmair J,Benz R,et al.Negative regulation of mitochondrial VDAC channels by C-Rafkinase.BMC Cell Biol,2002,3:14.
[63]林毅,陈书长.肝癌的治疗现状与展望[J].癌症进展杂志,2007,5(1):79-84.
[64]Hwang YH,Choi JY,Kim S,et al.Overexpression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma[J].Hepatol Res,2004,29(2):113-121.
[65]Tsuboi Y,Ichida T,Sugitani S,et al.Over-expression of extracellular signalregulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma[J].Liver Int,2004,24(5):432-436.
[66]Huynh H,Nguyen TT,Chow KH,et al.Over-expression of the mitogen-activated protein kinase(MAPK) kinase(MEK)-MAPK in hepatocellular carcinoma:its role in tumor progression and apoptosis[J].BMC Gastroenterol,2003,8(3):19.
[67]Schmidt CM,McKillop IH,Cahill PA,et al.Increased MAPK expression and activity in primary human hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 1997,236(1):54 - 58.
[68] Rahmani M, Davis EM, Bauer C, et al. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation [J]. J Biol Chem, 2005, 280(42):35217-35227.
[69] Fabregat I, Roncero C, Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer [J].Liver Int, 2007,27(2): 155-162.
[2]黄正京,周麦耕,王黎君.中国肝癌死亡率和乙肝病毒表面抗原携带率的地理分布研究[J].疾病监测,2007,22(4):242-245.
[3]Llovet JM,Bruix J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:Chemoembolization improves survival[J].Hepatology,2003,37(2):429-442
[4]Scott M,Wilhelm,Christopher Carter,Li Ya Tang,et al.BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J].Cancer Research,2004,64:7099-7109.
[5]Li Liu,Yichen Cao,Charles Chen,et al.Sorafenib blocks the RAF/MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J].Cancer Research,2006,66(24):11851-11858.
[6]Wilhelm S,Chien DS.BAY 43-9006:Preclinical data[J].Curr Pharm Des,2002,8(25):2255-2257.
[7]Llovet J,Ricci S,Mazzaferro V,et al.Sorafenib improves survival in advanced Hepatocellular Carcinoma(HCC):Results of a Phase Ⅲ randomized placebo-controlled trial(SHARP trial)[J].J Clin Oncol,2007 ASCO Annual Meeting Proceedings Part Ⅰ.Vol 25,No.18s(June 20 Supplement),2007:LBA1.
[8]McDermott DF,Sosman JA,Gonzalez R,et al.Double-blind randomized phase Ⅱ study of the combination of sorafenib and dacarbazine in patients with advanced melanoma:a report from the 11715 Study Group[J].J Clin Oncol,2008,26(13):2178-85.
[9]Flaherty KT,Lee RJ,Humphries R,et al.Phase Ⅰ trial of BAY 43-9006 in combination with carboplatin(C) and paclitaxel(P)[J].Proc Am Soc Clin Oncol,2003,22:710.
[10]Flaherty KT,Brose M,Schuchter LM,et al.Sorafenib combined with carboplatin and paclitaxel for metastatic melanoma:PFS and response versus B-Raf status.Ann Oncol,2006,17:ⅲ33.
[11]Adjei AA,Molina JR,Mandrekar SJ,et al.Phase Ⅰ study of Sorefenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer[J].Clin Cancer Res,2007,13(9):2684-2691.
[12]Azad NS,Posadas EM,Kwitkowski VE,et al.Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab.J Clin Oncol,2006 ASCO Annual Meeting Proceedings Part Ⅰ.Vol 24,No.18s(June 20 Supplement),2006:3004.
[13]Posadas EM,Kwitkowski V,Liel MS et al.Clinical synergism from combinational VEGF signal transduction inhibition in patients with advanced solid tumors-early results from a Phase Ⅰ study of sorafenib(BAY 43-9006)and bevacizumab[J].Eur J Cancer Suppl,2005,3:419.
[14]徐洪雨,高媛媛,武倩丽等.三氧化二砷抑制人肝癌细胞株增殖和诱导凋亡作用[J].世界华人消化杂志,2000,8(11):1233-1237.
[15]邓志华,蔡洪培,李石等.三氧化二砷对正常肝细胞及肝癌细胞株的影响[J].中华消化杂志,1999,19(4):227-279.
[16]陈洪,秦叔逵,陈惠英等.三氧化二砷对抗肝癌作用的实验研究[J].中华肝病杂志,2000,8(1):27-29.
[17]邬红霞,周艳,于志坚等.三氧化二砷联合羟基喜树碱抗肝癌作用的实验研究[J].临床肿瘤学杂志,2007,6(12):413-416.
[18]Wei Wang,Shu-Kui Qin,Bao-An Chen et al.Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma[J].World J Gastroenterol,2001,7(5):702-705.
[19]Bos JL.Ras oncogenes in human cancer:a review[J].Cancer Res,1989,49(17):4682-4689.
[20]张鹏,胡龙虎,周晋,等.三氧化二砷治疗急性早幼粒细胞白血病的机 制研究[J].白血病,1996,5(3):131-133.
[21]陈国强,陈赛娟,王振义,等.氧化砷注射液治疗早幼粒细胞白血病的机制及展望[J].中国中西医结合杂志,1998,18(10):581-582.
[22]杜彩文,李德锐,杜英城,等.三氧化二砷诱导人鼻咽低分化鳞癌裸鼠移植瘤细胞分化的研究[J].癌症,2003,22(1):21-25.
[23]Baj G,Arnulfo A,Deaglio S,et al.Arsenic trioxide and breast cancer:analysis of the apoptotic,differentiation and immuno-modulatory effects[J].J Breast Cancer Res Treat,2002,73(1):61-73.
[24]Zhu Q,Zhang JW,Zhu Ha,et al.Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk[J].J Blood,2002,99(3):1014-1022.
[25]邓友平,林晨,张雪艳,等.三氧化二砷诱导人胃腺癌SGC-7901细胞程序化死亡并降低c-myc基因的表达[J].药学学报,1999,34(5):1-4.
[26]邓志华,蔡洪培,李石,等.三氧化二砷对正常肝细胞及肝癌细胞株的影响.[J].中华消化杂志,1999,19(4):227-279.
[27]刘琳,秦叔逵,陈惠英,等.三氧化二砷对人肝癌细胞株选择性抑制作用的实验研究[J].临床肿瘤学杂志,1999,4(4):39-41.
[28]刘琳,秦叔逵,陈惠英,等.三氧化二砷选择性诱导人肝癌细胞凋亡及相关基因的实验研究[J].中华肝脏病杂志,2000,8(6):70-73.
[29]邓友平,林晨,张雪艳,等.三氧化二砷抗肿瘤作用的研究[J].中国中药杂志,1999,24(3):174-175.
[30]蔡洪培,谢渭芬,陈岳祥,等.三氧化二砷对腹腔荷瘤裸鼠的抗恶病质效应[J].第二军医大学学报,2002,23(3):279-280.
[31]闻勤生,罗俊卿,焦成松.三氧化二砷对肝癌HepG2细胞增殖的影响[J].第四军医大学学报,2001,22(9):828-830.
[32]闻勤生,罗俊卿,焦成松.三氧化二砷诱导肝癌细胞HepG2凋亡作用[J].第三军医大学学报,2001,23(8):913-914.
[33]沈忠英,沈健,陈铭华.氧化砷诱导食管癌细胞系细胞凋亡的研究[J].汕头大学医学院学报,2001,14(1):1-4.
[34]张勇,李志民,刘音.三氧化二砷局部注射治疗原发性肝癌的临床研究[J].中华医学写字杂志,2002,9(16):1246-1248.
[35]陈俊强,李绍森,彭民浩,等.三氧化二砷及6种抗癌药物对肝癌细胞株作用的对比研究[J].中国普外基础与临床杂志,2001,8(6):367-369.
[36]罗俊卿,闻勤生,焦成松.三氧化二砷对肝癌细胞增殖的影响[J].临床消化病杂志,2001,13(3):113-115.
[37]Wang W,Qin S K,Chen B A,et al.Experimental study on anti-tumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma[J].J World J Gastroenterol,2001,7(5):702-705.
[38]Richly H,Henning BF,Kupsch P,et al.Results of a Phase Ⅰ trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors[J].J Ann Oncol,2006,17(5):866-873.
[39]Abou-Alfa G,Johnson P,Knox J,et al.Preliminary results from a Phase Ⅱ,randomized,double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma[J].J European Journal of Cancer,2007,5(Suppl):3500.
[40]Kanzler S,Galle PR.Apoptosis and the liver[J].Semin Cancer Biol,2000,10:173-184.
[41]曾益新.肿瘤学[M].北京:人民卫生出版社,2003.209-236.
[42]Wyllie AH.Apoptosis and carcinognenesis.Eur J Cell Biol,1997,73(3):189-197.
[43]Askenazi A,D ixit VM.Death receptors:signaling and modulation[J].Science,1998,281(5381):1305-1308.
[44]Green D R,Reed J C.Mitochondrial and apoptosis[J].Science,1998,281(5381):1309-1312.
[45]Stewart J H,Nguyen D,Chen G A,et al.Induction of apoptosis in malignant pleuralmesothlioma cells by activaction of the Fas(APO-1/CD95) death signal pathway[J].J Thorac Cardiovase Surg,2002,123(2):295-302.
[46]Kroemer G,Reed J C.Mitochondrial control of cell death[J].Nat Med,2000,6(5):513-519.
[47]Susin SA,Lorenzo HK,Zamami N,et al.Moleuclar characterization of mitochondrial apoptosis inducing factor[J].Nature,1999,397(6718):441-446.
[48]Zoratti M and Szaboi Z.The mitochondrial permeability transition.Biochem Biophys Acta,1995,1241(2):139-176.
[49]Stewart J H,Nguyen D,Chen G A,et al.Induction of apoptosis in malignant pleural mesothlioma cells by activaction of the Fas(APO-1/CD95) death signal pathway[J].J Thorac Cardiovase Surg,2002,123(2):295-302.
[50]Herr I,Debatin K.Cellular stress response and apoptosis in cancer therapy[J].Blood,2001,98(9):2603-2604.
[51]Hascgawa J,Kamada S,Kamijke W,et al.Involvement ofCPP32/Yama(-like)protease in Fas-mediated apoptosis[J].Cancer Res,1996,56(8):1713-1718.
[52]Perkins C,Kim CN,Fang G,et al.Arsenic induces apoptosis of multi-drugresistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR,MRP,Bcl-2 or bcl-x(L)[J].Blood,2000,95(3):1014-1022.
[53]Pu YS,Hour TC,Chen J,et al.Arsenic trioxide as a novel anticancer agent against human transitional carcinoma characterizing its apoptotic pathway[J].Anticancer Drugs,2002,13(3):293-300.
[54]Soignet SL,Maslak P,Wang ZG,et al.Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide[J].New Engl J Med,1998,339(19):1341-1348.
[55]Akao Y,Mizoguchi H,Kojima S,et al.Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro:activation of caspases and down-regulation of Bcl-2 protein[J].Br J Haematol,1998,102(4):1055-1060.
[56]Shin S,SungBJ,Cho YS,et al.An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7[J|.Bio Chem,2001,40(4):1117-1123.
[57]鞠培新,石文君.三氧化二砷在诱导非小细胞肺癌NCI-H157细胞凋亡过程中对Survivin基因表达Caspase-3的影响[J].中国肿瘤临床,2007, 34(19):1097-1100.
[58]Jin S,Zhuo Y,Guo W,et al.P21-activated Kinase 1(Pakl)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization,phosphorylation of BAD,and Bcl-2 association[J].J Biol Chem,2005,280(26):24698-24705.
[59]Salomoni P,Wasik MA,Riedel RF,et al.Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant[J].J Exp Med 1998,187(12):1995-2007.
[60]Chen J,Fujii K,Zhang L,et al.Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism.Proc Natl Acad Sci USA,2001,98(14):7783-7788.
[61]Baumann B,Weber CK,Troppmair J,et al.Raf induces NF-kappaB by membrane shuttle kinase MEKK1,a signaling pathway critical for transformation.Proc N ATL ACAD Sci USA,2000,97(9):4615-4620.
[62]Le Mellay V,Troppmair J,Benz R,et al.Negative regulation of mitochondrial VDAC channels by C-Rafkinase.BMC Cell Biol,2002,3:14.
[63]林毅,陈书长.肝癌的治疗现状与展望[J].癌症进展杂志,2007,5(1):79-84.
[64]Hwang YH,Choi JY,Kim S,et al.Overexpression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma[J].Hepatol Res,2004,29(2):113-121.
[65]Tsuboi Y,Ichida T,Sugitani S,et al.Over-expression of extracellular signalregulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma[J].Liver Int,2004,24(5):432-436.
[66]Huynh H,Nguyen TT,Chow KH,et al.Over-expression of the mitogen-activated protein kinase(MAPK) kinase(MEK)-MAPK in hepatocellular carcinoma:its role in tumor progression and apoptosis[J].BMC Gastroenterol,2003,8(3):19.
[67]Schmidt CM,McKillop IH,Cahill PA,et al.Increased MAPK expression and activity in primary human hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 1997,236(1):54 - 58.
[68] Rahmani M, Davis EM, Bauer C, et al. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation [J]. J Biol Chem, 2005, 280(42):35217-35227.
[69] Fabregat I, Roncero C, Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer [J].Liver Int, 2007,27(2): 155-162.